Generics Awareness Month took center stage at the Mercury Drug Q-Plaza Branch in Cainta recently, where RHEA Generics, in support of the Department of Health (DOH) and in partnership with Mercury Drug ...

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...

HYDERABAD: A surge in the unsupervised use of popular diabetes and weight-loss drugs in Hyderabad has raised alarm among doctors, who warn that social media trends and peer influence are pushing many ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Novo Nordisk is leaning on clinical evidence, localised pricing and partnerships as its frontline defence in India’s brutal semaglutide price war unleashed after the Danish company’s patent expired on ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

At Dr. David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments. But recently, another word is coming up just as often — generics. "It is a ...

Indian pharma majors Sun Pharma, Dr Reddy’s, Glenmark, and Zydus Lifesciences on Saturday announced the launch of their generic versions of semaglutide injections, used for diabetes and weight ...

Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...

WASHINGTON, DC (Reuters) – President Donald Trump announced plans to impose a 25% or higher tariff on semiconductor and pharmaceutical imports, a move that could significantly impact India’s ...